Effects of Spectator Ligands on the Specific Recognition of Intrastrand Platinum-DNA Cross-links by High Mobility Group Box and TATA-binding Proteins* 210
暂无分享,去创建一个
[1] E. Raymond,et al. Oxaliplatin-induced damage of cellular DNA. , 2000, Molecular pharmacology.
[2] Seth M. Cohen,et al. HMG-domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts. , 2000, Biochemistry.
[3] J. Misset,et al. Oxaliplatin clinical activity: a review. , 2000, Critical reviews in oncology/hematology.
[4] S. Lippard,et al. Stopped-flow fluorescence studies of HMG-domain protein binding to cisplatin-modified DNA. , 2000, Biochemistry.
[5] S. Lippard,et al. Enhanced binding of the TATA-binding protein to TATA boxes containing flanking cisplatin 1,2-cross-links. , 2000, Biochemistry.
[6] S. Lippard,et al. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[7] P. Beale,et al. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. , 1999, Journal of inorganic biochemistry.
[8] J. Turchi,et al. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. , 1999, Biochemistry.
[9] C. Giandomenico,et al. Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.
[10] S. Lippard,et al. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. , 1999, Chemical reviews.
[11] A. Aguzzi,et al. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice , 1999, Nature Genetics.
[12] C. Pabo,et al. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins , 1999, Nature.
[13] J. Essigmann,et al. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. , 1998, Biochemistry.
[14] B. Viollet,et al. TATA Binding Protein Discriminates between Different Lesions on DNA, Resulting in a Transcription Decrease , 1998, Molecular and Cellular Biology.
[15] S. Lippard,et al. Solution Structure of a DNA Duplex Containing a Nitroxide Spin-Labeled Platinum d(GpG) Intrastrand Cross-Link Refined with NMR-Derived Long-Range Electron−Proton Distance Restraints , 1998 .
[16] P. Sadler,et al. PKA VALUES OF AQUA LIGANDS OF PLATINUM(II) ANTICANCER COMPLEXES : 1H, 15N AND 195PT NMR STUDIES OF CIS- AND TRANS- PTCL2(NH3)(CYCLOHEXYLAMINE) , 1998 .
[17] D. Moras,et al. Cisplatin‐ and UV‐damaged DNA lure the basal transcription factor TFIID/TBP , 1997, The EMBO journal.
[18] S. Lippard,et al. DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA. , 1997, Biochemistry.
[19] S. Lippard,et al. Crystal Structure of the Anticancer Drug Cisplatin Bound to Duplex DNA , 1996 .
[20] R. Rietbroek,et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. , 1996, Carcinogenesis.
[21] T Lagrange,et al. The general transcription factors of RNA polymerase II. , 1996, Genes & development.
[22] S. Lippard,et al. Repair of cisplatin--DNA adducts by the mammalian excision nuclease. , 1996, Biochemistry.
[23] D. Landsman,et al. The HMG-1 box protein family: classification and functional relationships. , 1995, Nucleic acids research.
[24] S. Lippard,et al. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct. , 1995, Biochemistry.
[25] P. Cary,et al. The Structure of the HMG Box and Its Interaction with DNA , 1995 .
[26] G. Chu,et al. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. , 1994, The Journal of biological chemistry.
[27] S. Lippard,et al. DNA binding properties of [Pt(NH3)(C6H11NH2)Cl2], a metabolite of an orally active platinum anticancer drug , 1992 .
[28] K. Comess,et al. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. , 1992, Biochemistry.
[29] S. Lippard,et al. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. , 1992, Science.
[30] R. Tarone,et al. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[31] C. Giandomenico,et al. A convenient preparation of the amminetrichloroplatinate(II) anion , 1987 .
[32] R. Ozols,et al. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. , 1986, The Journal of clinical investigation.
[33] R. Ozols,et al. Polyclonal antibodies to quantitate cis-diamminedichloroplatinum(II)--DNA adducts in cancer patients and animal models. , 1985, Environmental health perspectives.
[34] B. Winograd,et al. Promising new developments in cancer chemotherapy , 1999, Cancer Chemotherapy and Pharmacology.